FibroGen’s Lead Drug Fails Again, Stock Hits All-Time Low
FibroGen, Inc. (NASDAQ: FGEN) faced another setback as its flagship drug, pamrevlumab, failed to meet the required standards for treating […]
FibroGen’s Lead Drug Fails Again, Stock Hits All-Time Low Read More »
